STOCK TITAN
  1. Home
  2. News
  3. FWBI

First Wave BioPharma, Inc. - FWBI STOCK NEWS

Welcome to our dedicated page for First Wave BioPharma news (Ticker: FWBI), a resource for investors and traders seeking the latest updates and insights on First Wave BioPharma stock.

First Wave BioPharma, Inc. (FWBI) is a leading biopharmaceutical company dedicated to developing non-systemic, recombinant protein therapies targeting gastrointestinal diseases and related conditions. Headquartered in New York, NY, with scientific operations based in Langlade, France, First Wave BioPharma aims to be at the forefront of innovative treatments in the biotech industry.

The company's flagship development program is MS1819 recombinant lipase, which is in advanced stages of development for treating exocrine pancreatic insufficiency (EPI). This condition often affects patients with cystic fibrosis and chronic pancreatitis, and MS1819 offers a promising alternative to current enzyme replacement therapies.

Besides MS1819, First Wave BioPharma is working diligently on early-stage research projects aimed at preventing hospital-acquired infections, further solidifying its focus on significant unmet medical needs.

In 2024, First Wave BioPharma plans to advance its gastrointestinal (GI) development pipeline significantly. The company expects to add the Phase 3 Latiglutenase celiac disease program and multiple Phase 2 clinical programs featuring Capeserod and Adrulipase. These initiatives are contingent upon the potential merger with ImmunogenX, a deal that could mark a year of substantial growth for the company.

Recent news highlights multiple clinical and development milestones anticipated in 2024, including the initiation of a Phase 3 clinical trial investigating latiglutenase in celiac disease. This trial is pivotal for the company's future, given the significant growth potential it represents in treating celiac disease effectively.

For detailed information and the latest updates, reach out to First Wave BioPharma at their Boca Raton office or through their media contact at Tiberend Strategic Advisors, Inc.

News

First Wave BioPharma CEO to Present at the BIO CEO & Investor Conference 2024

Rhea-AI Summary
First Wave BioPharma, Inc. announced that its Chairman and CEO will present at the BIO CEO & Investor Conference to discuss the company's business strategy and recent achievements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.11%
Tags
conferences
-
News

First Wave BioPharma to Present at the DealFlow MicroCap Conference

Rhea-AI Summary
First Wave BioPharma, Inc. (FWBI) will present at the DealFlow MicroCap Conference to showcase its business and clinical development strategy for gastrointestinal diseases. The event will take place from January 30 to February 1, 2024, at the Caesars Atlantic City Hotel & Casino. The company's management team will conduct one-on-one meetings with registered investors to discuss recent corporate achievements and anticipated milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
conferences
-
News

First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico

Rhea-AI Summary
First Wave BioPharma, Inc. (FWBI) is set to present at the Sequire Investor Summit 2024, showcasing their business and clinical development strategy for gastrointestinal diseases. The event is scheduled for January 23-25, 2024, in San Juan, Puerto Rico, with Chairman and CEO James Sapirstein leading the presentation on January 24. The company aims to engage with investors and highlight recent corporate achievements and upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
conferences
News

First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024

Rhea-AI Summary
First Wave BioPharma, Inc. (NASDAQ: FWBI) anticipates multiple clinical and development milestones in 2024, including the initiation of a Phase 3 clinical trial investigating latiglutenase in celiac disease. The potential business combination with ImmunogenX could provide access to Phase 3-ready latiglutenase, a potential first-in-class, targeted, oral biotherapeutic for celiac disease. Latiglutenase has been reviewed by the GI Division of the U.S. FDA, with Phase 3 trials expected to begin in the second half of 2024. The company also plans to announce a significant non-dilutive financial investment from a strategic global pharmaceutical company for commercial rights to latiglutenase in the U.S. and Canada, as well as financing commitments from institutional investors to fund the drug’s development. In addition, the company has added capeserod, a selective 5-HT4 receptor partial agonist, to its pipeline and is moving rapidly to initiate Phase 2 clinical trials in 2024. The company has also signed a non-binding term sheet to sell its niclosamide inflammatory bowel disease (IBD) program to an undisclosed biopharmaceutical company. The potential transaction with ImmunogenX, if completed, will allow First Wave BioPharma to focus on late-stage development programs, including latiglutenase and capeserod.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none
-
News

First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced

Rhea-AI Summary
First Wave BioPharma, Inc. (NASDAQ: FWBI) announced agreements with certain holders of its existing warrants to exercise at a reduced price, resulting in approximately $4.8 million in gross proceeds. The new warrants will allow the purchase of up to 1,762,674 shares of common stock at an exercise price of $5.00 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
49.86%
Tags
none
-
News

First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program

Rhea-AI Summary
First Wave BioPharma, Inc. (NASDAQ: FWBI) to advance GI development pipeline with the addition of Phase 3 Latiglutenase celiac disease program and Phase 2 clinical programs Capeserod and Adrulipase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
49.86%
Tags
none
News

First Wave BioPharma Announces Entry into Term Sheet for Business Combination with ImmunogenX Establishing a Leading Late-Stage GI-Focused Biopharmaceutical Company

Rhea-AI Summary
First Wave BioPharma, Inc. (NASDAQ: FWBI) announces a business combination with ImmunogenX to acquire Phase 3-ready latiglutenase, a targeted oral biotherapeutic for celiac disease. The company aims to expand its late-stage gastrointestinal disease clinical pipeline and has signed a non-binding term sheet for the acquisition. The transaction is expected to be completed in the first half of 2024, following approval from stockholders and other closing conditions. The combined company plans to continue trading on Nasdaq under the ticker symbol 'FWBI'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.17%
Tags
none
-
News

First Wave BioPharma Announces 1-for-20 Reverse Stock Split and Results of the Special Meeting of Stockholders

Rhea-AI Summary
First Wave BioPharma, Inc. (NASDAQ: FWBI) announced stockholder approval of all proposals at the Special Meeting, including a 1-for-20 reverse stock split to regain compliance with the Nasdaq Capital Market's minimum bid price requirement of $1.00 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.67%
Tags
none
-
News

First Wave BioPharma to Participate in BIO Partnering @JPM During “J.P. Morgan Week 2024” 

Rhea-AI Summary
First Wave BioPharma, Inc. (NASDAQ: FWBI) is participating in BIO Partnering @JPM from January 8-12, 2024, in San Francisco. The company will conduct one-on-one meetings with investors and pharmaceutical companies to showcase its business and clinical development strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
conferences
News

First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Conference

Rhea-AI Summary
First Wave BioPharma, Inc. (NASDAQ: FWBI) announced that its CEO will moderate a panel discussion on cross-border biopharma collaboration during the Longwood Healthcare Leaders San Francisco CEO Conference. The panel will include industry leaders from WuXi, Karyopharm, and TealTech, and will take place on January 6, 2024, prior to the 42nd Annual JP Morgan Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none

FAQ

What is the current stock price of First Wave BioPharma (FWBI)?

The current stock price of First Wave BioPharma (FWBI) is $2.96 as of May 17, 2024.

What is the market cap of First Wave BioPharma (FWBI)?

The market cap of First Wave BioPharma (FWBI) is approximately 6.0M.

What is First Wave BioPharma, Inc.'s core business?

First Wave BioPharma focuses on developing non-systemic, recombinant protein therapies for gastrointestinal diseases and related conditions.

What is MS1819 recombinant lipase?

MS1819 is First Wave BioPharma's lead development program, targeting exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis.

Where is First Wave BioPharma headquartered?

The company is headquartered in New York, NY, with scientific operations based in Langlade, France.

What are the significant upcoming milestones for First Wave BioPharma in 2024?

Key milestones include the initiation of a Phase 3 clinical trial for latiglutenase in celiac disease and progression of Phase 2 clinical programs around Capeserod and Adrulipase.

How can I contact First Wave BioPharma for more information?

You can contact them at their Boca Raton office or through their media contact, Tiberend Strategic Advisors, Inc. David Schemelia at (609) 468-9325 or dschemelia@tiberend.com.

What potential growth opportunities are there for First Wave BioPharma?

The potential merger with ImmunogenX and the advancement of the GI development pipeline are expected to drive significant growth in 2024.

What research is First Wave BioPharma conducting besides MS1819?

The company is engaged in early-stage research for the prevention of hospital-acquired infections.

What is the significance of the Phase 3 latiglutenase program?

It represents a major advancement in treating celiac disease and could mark substantial growth for the company.

How has First Wave BioPharma performed in recent advancements?

The company has shown significant progress with major upcoming clinical trials and potential mergers, marking a promising future.

What impact does the merger with ImmunogenX have on First Wave BioPharma?

The merger is expected to facilitate the addition of advanced clinical programs, driving substantial growth and development in 2024.

Stock FWBI logo
First Wave BioPharma, Inc.

Nasdaq:FWBI

FWBI Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

FWBI Stock Data

5.99M
2.75M
5.66%
1.46%
2.3%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
BOCA RATON